DK1310571T3
(da)
*
|
2001-11-13 |
2006-06-19 |
Univ Pennsylvania |
Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden
|
EP1453547B1
(en)
|
2001-12-17 |
2016-09-21 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
ES2411479T3
(es)
*
|
2003-09-30 |
2013-07-05 |
The Trustees Of The University Of Pennsylvania |
Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos
|
WO2006078279A2
(en)
|
2004-04-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
EP1742657B1
(en)
|
2004-04-28 |
2013-11-06 |
The Trustees of The University of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
EP3085389A1
(en)
*
|
2005-04-07 |
2016-10-26 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an aav vector
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
CA2649182C
(en)
|
2006-04-07 |
2018-01-02 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
CN101495624A
(zh)
*
|
2006-04-28 |
2009-07-29 |
宾夕法尼亚州立大学托管会 |
衣壳免疫原性降低的经修饰aav载体及其用途
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
EP2191001B1
(en)
*
|
2007-04-09 |
2016-06-08 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
US8632764B2
(en)
*
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
DK2425000T3
(da)
*
|
2009-04-30 |
2019-05-13 |
Univ Pennsylvania |
Sammensætninger rettet mod ledende luftvejsceller omfattende konstrukter af adeno-associeret virus
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
WO2011041502A1
(en)
|
2009-10-01 |
2011-04-07 |
The Trustees Of The University Of Pennsylvania |
Aav vectors expressing sec1o for treating kidney damage
|
JP5922095B2
(ja)
|
2010-03-29 |
2016-05-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
薬理学的に誘導される導入遺伝子アブレーション系
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
ES2698203T3
(es)
|
2010-04-23 |
2019-02-01 |
Univ Massachusetts |
Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
EP2634253B1
(en)
*
|
2010-10-27 |
2016-05-11 |
Jichi Medical University |
Adeno-associated virus virions for transferring genes into neural cells
|
US9409953B2
(en)
*
|
2011-02-10 |
2016-08-09 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
EP2675902B1
(en)
|
2011-02-17 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
US20140031418A1
(en)
|
2011-04-20 |
2014-01-30 |
The Trustees Of The University Of Pennsylvania |
Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
EP2699270B1
(en)
|
2011-04-22 |
2017-06-21 |
The Regents of The University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
EP3795581A3
(en)
*
|
2011-08-24 |
2021-06-09 |
The Board of Trustees of the Leland Stanford Junior University |
New avv capsid proteins for nucleic acid transfer
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
US9611305B2
(en)
|
2012-01-06 |
2017-04-04 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
JP6385920B2
(ja)
*
|
2012-05-09 |
2018-09-05 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
アデノ随伴ウイルスプラスミド及びベクター
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
WO2014011210A1
(en)
|
2012-07-11 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
BR112015002168A2
(pt)
|
2012-08-01 |
2017-11-07 |
Nationwide Childrens Hospital |
liberação intratecal de vírus 9 adeno-associado recombinante
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
US9636370B2
(en)
*
|
2012-09-28 |
2017-05-02 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
WO2014055960A1
(en)
|
2012-10-05 |
2014-04-10 |
Genelux Corporation |
Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
JP2016514152A
(ja)
*
|
2013-03-13 |
2016-05-19 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
アデノ随伴ウイルスベクターおよびその使用の方法
|
AU2014241078B2
(en)
|
2013-03-14 |
2020-03-12 |
University Of Florida Research Foundation, Inc. |
Di-amino acid repeat-containing proteins associated with ALS
|
IL293294B2
(en)
*
|
2013-03-15 |
2023-04-01 |
Univ North Carolina Chapel Hill |
Methods and compounds for ligation of paired aav glycan vectors
|
PT2984166T
(pt)
|
2013-03-15 |
2020-07-16 |
Univ Pennsylvania |
Composições para tratar mps i
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
WO2014194132A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
EP3044318B1
(en)
|
2013-09-13 |
2019-05-01 |
California Institute of Technology |
Selective recovery
|
JP6985795B2
(ja)
|
2013-09-26 |
2021-12-22 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
標的遺伝子治療のための合成コンビナトリアルaavカプシドライブラリー
|
CN106029107A
(zh)
*
|
2013-10-07 |
2016-10-12 |
基罗米克有限责任公司 |
使用疾病特异性启动子治疗心血管疾病的组合物和方法
|
ES2857751T3
(es)
|
2013-10-11 |
2021-09-29 |
Massachusetts Eye & Ear Infirmary |
Métodos para predecir secuencias de virus ancestrales y usos de los mismos
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
LT3116900T
(lt)
|
2014-03-09 |
2020-12-10 |
The Trustees Of The University Of Pennsylvania |
Kompozicijos, naudotinos ornitino transkarbamilazės (otc) nepakankamumo gydymui
|
BR112016020783A2
(pt)
|
2014-03-10 |
2017-10-03 |
Uniqure Ip Bv |
Vetores de aav adicionalmente melhorados produzidos em células de inseto
|
AU2015231439B2
(en)
|
2014-03-17 |
2019-11-14 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
MX365658B
(es)
|
2014-05-13 |
2019-06-10 |
Univ Pennsylvania |
Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
BR112017005892A2
(pt)
|
2014-09-24 |
2017-12-12 |
Hope City |
variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
AU2015335923B2
(en)
|
2014-10-21 |
2021-04-29 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
RU2716991C2
(ru)
*
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
AU2015342997B2
(en)
*
|
2014-11-05 |
2021-11-18 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
JP6863891B2
(ja)
|
2014-11-14 |
2021-04-21 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
調節性ポリヌクレオチド
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Preparations and methods for the treatment of amyotrophic lateral sclerosis
|
CN107532173A
(zh)
|
2014-11-21 |
2018-01-02 |
北卡罗来纳-查佩尔山大学 |
靶向中枢神经系统的aav载体
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
AU2015364636B9
(en)
|
2014-12-16 |
2021-12-02 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for Juvenile Batten Disease
|
ES2900973T3
(es)
|
2015-01-07 |
2022-03-21 |
UNIV AUTòNOMA DE BARCELONA |
Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
|
JP6832280B2
(ja)
|
2015-01-16 |
2021-02-24 |
ユニバーシティ オブ ワシントンUniversity of Washington |
新規のマイクロジストロフィンおよび使用の関連する方法
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
SG11201707063TA
(en)
|
2015-03-02 |
2017-09-28 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
JP2018509164A
(ja)
|
2015-03-10 |
2018-04-05 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
組換えGlut1アデノ随伴ウイルスベクターコンストラクトおよびGlut1発現を回復させる方法
|
CN107532177A
(zh)
*
|
2015-03-24 |
2018-01-02 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
US10881548B2
(en)
|
2015-05-07 |
2021-01-05 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
WO2016183297A1
(en)
*
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
EA201792500A1
(ru)
|
2015-05-13 |
2018-04-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Aav-опосредованная экспрессия антител против гриппа и способы их использования
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
AU2016298394C1
(en)
*
|
2015-07-30 |
2024-02-15 |
Massachusetts Eye And Ear Infirmary |
Ancestral virus sequences and uses thereof
|
CN108472314A
(zh)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
AU2016302335B2
(en)
|
2015-08-06 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
GLP-1 and use thereof in compositions for treating metabolic diseases
|
JP6905755B2
(ja)
|
2015-08-25 |
2021-07-21 |
デューク ユニバーシティ |
Rnaガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
|
JP6877408B2
(ja)
|
2015-08-31 |
2021-05-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ペット治療用aav−epo
|
IL296929A
(en)
|
2015-09-24 |
2022-12-01 |
Univ Pennsylvania |
A preparation and method for the treatment of a complement-mediated disease
|
IL257628B2
(en)
|
2015-09-28 |
2023-04-01 |
Univ North Carolina Chapel Hill |
Methods and compositions for stealth virus antibody vectors
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
WO2017066764A2
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
US20200181644A1
(en)
*
|
2015-10-22 |
2020-06-11 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial aav3 capsid library
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
EP4316512A3
(en)
|
2015-10-28 |
2024-04-24 |
The Trustees of The University of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
KR102200642B1
(ko)
|
2015-11-05 |
2021-01-12 |
뱀부 테라퓨틱스 인코포레이티드 |
유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
ES2869284T3
(es)
*
|
2015-12-11 |
2021-10-25 |
California Inst Of Techn |
Péptidos de diana para dirigir virus adenoasociados (AAV)
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
EP4085934A1
(en)
|
2015-12-11 |
2022-11-09 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
CN116236591A
(zh)
|
2015-12-11 |
2023-06-09 |
马萨诸塞眼科耳科诊所 |
用于将核酸递送至耳蜗和前庭细胞的材料和方法
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
JP7057281B2
(ja)
|
2015-12-14 |
2022-04-19 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
CA3008280A1
(en)
*
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
BR112018015751A2
(pt)
|
2016-02-03 |
2019-02-05 |
Univ Pennsylvania |
terapia gênica para tratamento de mucopolissacaridose tipo i
|
US20190038777A1
(en)
|
2016-02-05 |
2019-02-07 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
EP3413928B1
(en)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
KR102574810B1
(ko)
|
2016-04-15 |
2023-09-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
습성 연령 관련 황반 변성의 치료를 위한 조성물
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
KR102450833B1
(ko)
|
2016-04-15 |
2022-10-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
혈우병 a 치료용 유전자 요법
|
SG11201808812RA
(en)
*
|
2016-04-15 |
2018-11-29 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
CN109715657A
(zh)
|
2016-04-15 |
2019-05-03 |
高山免疫科学股份有限公司 |
Cd80变体免疫调节蛋白及其用途
|
KR20190008237A
(ko)
|
2016-04-15 |
2019-01-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
KR20230051602A
(ko)
|
2016-04-15 |
2023-04-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US10882886B2
(en)
*
|
2016-05-03 |
2021-01-05 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
PT3445773T
(pt)
|
2016-05-13 |
2023-03-13 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e métodos de utilização das mesmas
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
AU2017284198B2
(en)
|
2016-06-13 |
2023-09-28 |
The University Of North Carolina At Chapel Hill |
Optimized CLN1 genes and expression cassettes and their use
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
KR102526506B1
(ko)
|
2016-07-08 |
2023-05-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
CN109715650B
(zh)
*
|
2016-07-26 |
2024-03-08 |
生物马林药物股份有限公司 |
新颖腺相关病毒衣壳蛋白
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
BR112019001815A2
(pt)
|
2016-07-29 |
2019-05-07 |
The Regents Of The University Of California |
vírions do vírus adeno-associado com capsídeo variante e seus métodos de uso
|
CA3035522A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
CN110352245A
(zh)
|
2016-10-20 |
2019-10-18 |
高山免疫科学股份有限公司 |
可分泌变体免疫调节蛋白和工程化细胞疗法
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
KR102604096B1
(ko)
|
2016-12-30 |
2023-11-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
윌슨병을 치료하기 위한 유전자 치료
|
CN110325199A
(zh)
|
2016-12-30 |
2019-10-11 |
宾夕法尼亚州立大学托管会 |
用于治疗苯丙酮尿症的基因疗法
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
WO2018144709A2
(en)
|
2017-02-01 |
2018-08-09 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
JP2020507349A
(ja)
|
2017-02-09 |
2020-03-12 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー(nk)細胞ならびにその組成物および方法
|
WO2018152485A1
(en)
|
2017-02-20 |
2018-08-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
AU2018224044B2
(en)
|
2017-02-21 |
2024-01-25 |
The Uab Research Foundation |
Modified AAV capsid proteins and uses thereof
|
US11518991B2
(en)
|
2017-02-24 |
2022-12-06 |
Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
|
SG10201912976WA
(en)
*
|
2017-02-28 |
2020-02-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
SG10201913833PA
(en)
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
WO2018160849A1
(en)
|
2017-03-01 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
WO2018158397A1
(en)
|
2017-03-02 |
2018-09-07 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
WO2018170026A2
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
JP2020509776A
(ja)
|
2017-03-16 |
2020-04-02 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Pd−l1バリアント免疫調節タンパク質及びその使用
|
JP7287940B2
(ja)
|
2017-03-24 |
2023-06-06 |
ランケナウ・インスティテュート・フォー・メディカル・リサーチ |
ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物
|
SG11201909136PA
(en)
|
2017-03-31 |
2019-10-30 |
Staidson Beijing Biopharmaceuticals Co Ltd |
Shrna expression cassette, polynucleotide sequence carrying the same, and use thereof
|
WO2018189208A1
(en)
|
2017-04-10 |
2018-10-18 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
BR112019021569A2
(pt)
|
2017-04-14 |
2020-05-12 |
Regenxbio Inc. |
Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
WO2018195110A1
(en)
*
|
2017-04-17 |
2018-10-25 |
University Of Florida Research Foundation, Incorporated |
Regolation of ran translation by pkr and eif2a-p pathways
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
AU2018261790A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
WO2018209154A1
(en)
*
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses
|
JP7273730B2
(ja)
|
2017-05-11 |
2023-05-15 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
神経セロイドリポフスチン症のための遺伝子療法
|
EP3630986A4
(en)
|
2017-05-31 |
2021-08-11 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR THE TREATMENT OF PEROXYSOMA DISORDERS
|
EP3638316A4
(en)
|
2017-06-14 |
2021-03-24 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR EYE DISORDERS
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
WO2019008157A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
NOVEL POLYNUCLEOTIDES ENCODING HUMAN FKRP PROTEIN
|
US11497576B2
(en)
|
2017-07-17 |
2022-11-15 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
US20200207830A1
(en)
|
2017-07-27 |
2020-07-02 |
Novartis Ag |
Trem2 mutants resistant to sheddase cleavage
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavを送達するための組成物および方法
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
WO2019060454A2
(en)
|
2017-09-20 |
2019-03-28 |
4D Molecular Therapeutics Inc. |
CAPSID VARIANT ADENO-ASSOCIATED VIRUSES AND METHODS OF USE
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Sod1二重発現ベクターおよびその使用
|
JP7449223B2
(ja)
|
2017-09-22 |
2024-03-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ii型を治療するための遺伝子療法
|
AU2018342105B2
(en)
|
2017-09-26 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
TW201925223A
(zh)
|
2017-10-18 |
2019-07-01 |
美商艾爾潘免疫科學有限公司 |
變異型icos 配位體免疫調節蛋白及相關組合物及方法
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
AU2018350992A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
EP3697448A1
(en)
|
2017-10-20 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant aav9-derived vector
|
SG11202004545XA
(en)
|
2017-11-27 |
2020-06-29 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
MX2020005673A
(es)
|
2017-11-30 |
2020-12-03 |
Univ Pennsylvania |
Terapia génica para mucopolisacaridosis iiib.
|
AU2018375164A1
(en)
|
2017-11-30 |
2020-06-04 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for Mucopolysaccharidosis IIIA
|
WO2019126329A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos Llc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
JP2021511020A
(ja)
|
2018-01-17 |
2021-05-06 |
アドリーナス セラピューティクス, インコーポレイテッド |
21−ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
BR112020017278A2
(pt)
*
|
2018-02-27 |
2020-12-22 |
The Trustees Of The University Of Pennsylvania |
Vetores de vírus adenoassociado (aav), vetores de aav tendo desamidação de capsídeos reduzida e usos para os mesmos
|
WO2019168961A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
AU2019234918A1
(en)
*
|
2018-03-16 |
2020-09-17 |
Research Institute At Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
SG11202009452WA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
KR20210015770A
(ko)
|
2018-04-05 |
2021-02-10 |
제네똥 |
감소된 간 향성을 갖는 AAV9과 AAVrh74의 하이브리드 재조합 아데노-관련 바이러스 세로타입
|
EP3787771A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Scalable clarification process for recombinant aav production
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
CN112154209A
(zh)
|
2018-05-08 |
2020-12-29 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白—连接子聚合蛋白
|
SG11202010830WA
(en)
|
2018-05-09 |
2020-11-27 |
Biomarin Pharm Inc |
Methods of treating phenylketonuria
|
KR20210010491A
(ko)
|
2018-05-11 |
2021-01-27 |
매사추세츠 아이 앤드 이어 인퍼머리 |
아데노-연관 바이러스의 간-특이적 향성
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
MA52631A
(fr)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics Inc |
Compositions et méthodes pour le traitement de la maladie de parkinson
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
ES2966045T3
(es)
|
2018-06-04 |
2024-04-18 |
Calidi Biotherapeutics Inc |
Vehículos basados en células para la potenciación de la terapia viral
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
US20210301305A1
(en)
|
2018-06-13 |
2021-09-30 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (utr) for aav production
|
WO2019241535A2
(en)
|
2018-06-14 |
2019-12-19 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant aav production
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
WO2020033842A1
(en)
|
2018-08-10 |
2020-02-13 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CN113164556A
(zh)
|
2018-08-30 |
2021-07-23 |
特纳亚治疗股份有限公司 |
用心肌蛋白和ascl1进行的心脏细胞重编程
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
CA3114621A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
EP3862012A4
(en)
|
2018-10-01 |
2022-08-17 |
Toru Miyazaki |
THERAPEUTIC FOR NEURODEGENERATIVE DISEASES
|
MX2021003869A
(es)
|
2018-10-01 |
2021-09-08 |
Univ Pennsylvania |
Composiciones útiles para tratar la gangliosidosis gm1.
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
CA3115248A1
(en)
*
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
CA3115524A1
(en)
|
2018-10-15 |
2020-04-23 |
Win Den Cheung |
Methods for measuring the infectivity of replication defective viral vectors and viruses
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
EP3870695A1
(en)
|
2018-10-22 |
2021-09-01 |
University of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
CA3116192A1
(en)
|
2018-11-06 |
2020-05-14 |
Calidi Biotherapeutics, Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
JP7069426B2
(ja)
|
2018-11-16 |
2022-05-17 |
アステラス製薬株式会社 |
ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
WO2020113141A2
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
KR20210112339A
(ko)
|
2019-01-04 |
2021-09-14 |
울트라제닉스 파마수티컬 인코포레이티드 |
윌슨병을 치료하기 위한 유전자 요법 구축물
|
EP3911741A1
(en)
|
2019-01-14 |
2021-11-24 |
University of Rochester |
Targeted nuclear rna cleavage and polyadenylation with crispr-cas
|
US20220064671A1
(en)
|
2019-01-18 |
2022-03-03 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
CN113924115A
(zh)
|
2019-01-31 |
2022-01-11 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
TW202045730A
(zh)
|
2019-02-22 |
2020-12-16 |
賓州大學委員會 |
用於治療grn相關的成年發病型神經系統退化症之重組腺相關病毒
|
CN113677801A
(zh)
|
2019-02-25 |
2021-11-19 |
诺华股份有限公司 |
治疗bietti晶体营养不良的组合物和方法
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
JP2022525848A
(ja)
|
2019-02-26 |
2022-05-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クラッベ病の治療に有用な組成物
|
JP2022524951A
(ja)
|
2019-02-27 |
2022-05-11 |
アクティム・セラピューティクス・インコーポレイテッド |
腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
US20220204574A1
(en)
|
2019-03-25 |
2022-06-30 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
US20220143221A1
(en)
|
2019-04-03 |
2022-05-12 |
Regenxbio, Inc. |
Gene Therapy For Eye Pathologies
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
SI3953483T1
(sl)
|
2019-04-11 |
2024-02-29 |
Regenxbio Inc. |
Postopki gelske izključitvene kromatografije za karakterizacijo spojin rekombinantnih adeno-povezanih virusov
|
EP4272817A3
(en)
|
2019-04-19 |
2024-01-24 |
RegenxBio Inc. |
Adeno-associated virus vector formulations and methods
|
CA3137284A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
EP3976077A4
(en)
*
|
2019-04-29 |
2023-08-30 |
The Trustees of The University of Pennsylvania |
NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING THEM
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
EP3969061A1
(en)
|
2019-05-14 |
2022-03-23 |
BioMarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
US20220233721A1
(en)
|
2019-05-28 |
2022-07-28 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
AU2020284255A1
(en)
|
2019-05-30 |
2022-01-06 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
CA3145662A1
(en)
|
2019-07-02 |
2021-01-07 |
M6P Therapeutics |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021005210A1
(en)
|
2019-07-11 |
2021-01-14 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
WO2021016453A1
(en)
|
2019-07-23 |
2021-01-28 |
University Of Rochester |
Targeted rna cleavage with crispr-cas
|
CA3145112A1
(en)
|
2019-07-26 |
2021-02-04 |
Chunping Qiao |
Engineered nucleic acid regulatory element and methods of uses thereof
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
TW202112797A
(zh)
|
2019-08-16 |
2021-04-01 |
日商摩大力斯醫療公司 |
經由靶向lama1基因治療肌肉萎縮症的方法
|
WO2021034920A1
(en)
*
|
2019-08-20 |
2021-02-25 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
JP2022545967A
(ja)
|
2019-08-26 |
2022-11-01 |
リジェネックスバイオ インコーポレイテッド |
完全ヒト翻訳後修飾抗VEGF Fabを用いる糖尿病性網膜症の処置
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
KR20220079857A
(ko)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CN114521143A
(zh)
|
2019-09-19 |
2022-05-20 |
吉尼松公司 |
减轻fkrp心脏毒性的基因治疗表达系统
|
JP2022550435A
(ja)
|
2019-10-04 |
2022-12-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
組換えaavの改善された治療的使用のための方法
|
CN114728049A
(zh)
|
2019-10-07 |
2022-07-08 |
再生生物股份有限公司 |
腺相关病毒载体药物组合物和方法
|
US20220362402A1
(en)
|
2019-10-08 |
2022-11-17 |
Exhaura, Ltd. |
Compositions and methods for ocular therapy
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
IL292297A
(en)
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for the treatment of Niemann-Pick type c disease
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
EP4055034A4
(en)
*
|
2019-11-08 |
2024-05-29 |
Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
MX2022006427A
(es)
|
2019-11-28 |
2022-09-07 |
Regenxbio Inc |
"construcciones para terapia génica con microdistrofina y uso de las mismas.
|
US20230047424A1
(en)
|
2019-12-09 |
2023-02-16 |
Ucl Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
MX2022007135A
(es)
|
2019-12-10 |
2022-09-19 |
Takeda Pharmaceuticals Co |
Vectores de virus adenoasociados para el tratamiento del síndrome de hunter.
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
AU2021211416A1
(en)
|
2020-01-22 |
2022-08-11 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis I with fully-human glycosylated human alpha-L-iduronidase (IDUA)
|
WO2021154963A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
JP2023512043A
(ja)
|
2020-01-29 |
2023-03-23 |
レジェンクスバイオ インコーポレーテッド |
ムコ多糖症ivaの治療
|
WO2021155337A1
(en)
|
2020-02-02 |
2021-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
CA3168903A1
(en)
|
2020-02-07 |
2021-08-12 |
University Of Rochester |
Ribozyme-mediated rna assembly and expression
|
JP2023513211A
(ja)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
タンパク質合成を増強するためのCRISPR-Cas13による標的RNA翻訳
|
MX2022009982A
(es)
|
2020-02-14 |
2022-09-12 |
Ultragenyx Pharmaceutical Inc |
Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5.
|
JP2023515820A
(ja)
|
2020-02-28 |
2023-04-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
メープルシロップ尿症の遺伝子治療
|
CA3173567A1
(en)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
EP4118098A1
(en)
|
2020-03-11 |
2023-01-18 |
The Trustees of The University of Pennsylvania |
Methods and composition for gene delivery using an engineered viral particle
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
JP2023519307A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
Crispr-cas13によるウイルスrnaの標的化破壊
|
TW202202520A
(zh)
|
2020-03-27 |
2022-01-16 |
比利時商Ucb生物製藥公司 |
自主旋鈕(autonomous knob)結構域肽
|
WO2021195525A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Crispr-cas13 crrna arrays
|
EP4127189A1
(en)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
TW202204383A
(zh)
|
2020-04-10 |
2022-02-01 |
美商碩拿生物科學有限責任公司 |
用於治療蛋白質聚集病症之組合物及方法
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
CA3180658A1
(en)
|
2020-04-22 |
2021-10-28 |
Indapta Therapeutics, Inc. |
Natural killer (nk) cell compositions and methods for generating same
|
WO2021222168A2
(en)
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
JP2023524291A
(ja)
*
|
2020-05-05 |
2023-06-09 |
デューク ユニバーシティ |
異種間適合性アデノ随伴ウイルス組成物およびその使用方法
|
MX2022014245A
(es)
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de la enfermedad de krabbe.
|
US20230304034A1
(en)
|
2020-05-12 |
2023-09-28 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
BR112022023106A2
(pt)
|
2020-05-13 |
2023-01-17 |
Voyager Therapeutics Inc |
Redirecionamento de tropismo de capsídeos de aav
|
AR122079A1
(es)
|
2020-05-13 |
2022-08-10 |
Akouos Inc |
Composiciones y métodos para tratar la perdida auditiva asociada a kcnq4
|
CN116801911A
(zh)
|
2020-05-13 |
2023-09-22 |
阿库斯股份有限公司 |
用于治疗slc26a4相关听力损失的组合物和方法
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
WO2021248038A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
CA3183153A1
(en)
|
2020-06-17 |
2021-12-23 |
Christian HINDERER |
Compositions and methods for treatment of gene therapy patients
|
CA3182313A1
(en)
|
2020-06-19 |
2021-12-23 |
Isabelle Richard |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
BR112022026997A2
(pt)
*
|
2020-07-07 |
2023-03-07 |
Univ Texas |
Vetor de vírus adeno-associado para quadro de leitura aberto dwarf
|
US20240018524A1
(en)
|
2020-07-10 |
2024-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating epilepsy
|
BR112023000305A2
(pt)
|
2020-07-10 |
2023-03-21 |
Genethon |
Promotor, sistema de expressão e composição farmacêutica
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
JP2023534464A
(ja)
|
2020-07-15 |
2023-08-09 |
ユニバーシティ オブ ロチェスター |
dCas13-RNase融合タンパク質による標的RNAの切断
|
AU2021315876A1
(en)
|
2020-07-27 |
2023-02-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
CN115927398A
(zh)
*
|
2020-07-29 |
2023-04-07 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
US20230295656A1
(en)
|
2020-08-06 |
2023-09-21 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CA3192052A1
(en)
|
2020-08-17 |
2022-02-24 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
MX2023002293A
(es)
|
2020-08-24 |
2023-05-19 |
Univ Pennsylvania |
Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica.
|
AR123358A1
(es)
|
2020-08-26 |
2022-11-23 |
Univ Pennsylvania |
Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio adulto asociada a la grn
|
CA3194019A1
(en)
|
2020-09-04 |
2022-03-10 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
TW202228646A
(zh)
|
2020-10-07 |
2022-08-01 |
美商銳進科斯生物股份有限公司 |
諸如凝膠調配物之用於脈絡膜上投與之調配物
|
EP4225381A1
(en)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
CA3193697A1
(en)
|
2020-10-07 |
2022-04-14 |
Joseph Bruder |
Adeno-associated viruses for ocular delivery of gene therapy
|
JP2023544797A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
脈絡膜上投与用の、高粘度製剤などの製剤
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
IL301643A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Gene therapy for ocular manifestations of CLN2 disease
|
EP4225906A1
(en)
|
2020-10-09 |
2023-08-16 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
TW202229315A
(zh)
|
2020-10-18 |
2022-08-01 |
賓州大學委員會 |
改良的腺相關病毒(aav)載體及其用途
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
EP4236999A1
(en)
|
2020-10-28 |
2023-09-06 |
RegenxBio Inc. |
Vectorized anti-tnf-alfa antibodies for ocular indications
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
IL302128A
(en)
|
2020-11-02 |
2023-06-01 |
Biomarin Pharm Inc |
A process for the enrichment of adeno-associated virus
|
MX2023005218A
(es)
|
2020-11-03 |
2023-05-16 |
Pfizer |
Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico.
|
US20240024507A1
(en)
|
2020-12-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
JP2023551533A
(ja)
|
2020-12-01 |
2023-12-08 |
アコーオス インコーポレイテッド |
前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法
|
US20230414785A1
(en)
|
2020-12-01 |
2023-12-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and uses thereof for treatment of angelman syndrome
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
US20240167054A1
(en)
|
2020-12-16 |
2024-05-23 |
Regenxbio Inc. |
Method of producing a recombinant virus particle
|
US20240043869A1
(en)
|
2020-12-23 |
2024-02-08 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
KR20230127263A
(ko)
|
2020-12-29 |
2023-08-31 |
아카우오스, 인크. |
Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
CN116848255A
(zh)
|
2021-01-21 |
2023-10-03 |
再生生物股份有限公司 |
改进的重组多肽和病毒的生产
|
MX2023008738A
(es)
*
|
2021-01-25 |
2023-09-12 |
Trames Bio Inc |
Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
JP2024506296A
(ja)
|
2021-02-05 |
2024-02-13 |
メイズ セラピューティクス, インコーポレイテッド |
スタッファーポリヌクレオチド配列を含むベクター
|
WO2022173847A2
(en)
*
|
2021-02-09 |
2022-08-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
CA3209611A1
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
BR112023016983A2
(pt)
|
2021-02-26 |
2023-11-07 |
Takeda Pharmaceuticals Co |
Vetor de vírus adeno-associado recombinante, método para tratar doença de fabry, composição farmacêutica, célula, e, método de expressão da enzima ¿-gal em uma célula
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
AR125143A1
(es)
|
2021-03-19 |
2023-06-14 |
Adrenas Therapeutics Inc |
Terapias génicas para la deficiencia de la 21-hidroxilasa
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
EP4320139A1
(en)
|
2021-04-05 |
2024-02-14 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
EP4323520A1
(en)
|
2021-04-12 |
2024-02-21 |
The Trustees of The University of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
BR112023021971A2
(pt)
|
2021-04-23 |
2024-02-20 |
Univ Pennsylvania |
Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos
|
CA3216146A1
(en)
|
2021-04-23 |
2022-10-27 |
Douglas Anderson |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
CN117377500A
(zh)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
具有改善的组织向性的腺相关病毒载体衣壳
|
WO2022232141A1
(en)
|
2021-04-26 |
2022-11-03 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
EP4334454A2
(en)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Novel aav vectors and methods and uses thereof
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
EP4352079A1
(en)
*
|
2021-06-08 |
2024-04-17 |
NF2 Therapeutics, Inc. |
Compositions and methods for treating neurofibromatic disorders
|
CA3222911A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
JP2023002483A
(ja)
|
2021-06-22 |
2023-01-10 |
ファイザー・インク |
昆虫細胞におけるアデノ随伴ウイルスベクターの産生
|
WO2022272056A2
(en)
*
|
2021-06-24 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
WO2023283649A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
EP4359551A2
(en)
*
|
2021-07-23 |
2024-05-01 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
TW202320836A
(zh)
|
2021-07-30 |
2023-06-01 |
宮崎徹 |
缺血性疾病之治療劑
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
AR126870A1
(es)
*
|
2021-08-25 |
2023-11-22 |
Canbridge Pharmaceuticals Inc |
PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GALACTOSIDASA Y SU USO PARA TRATAR LA ENFERMEDAD DE FABRY
|
AU2022335593A1
(en)
*
|
2021-08-25 |
2024-03-14 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
JP7175044B1
(ja)
|
2021-09-24 |
2022-11-18 |
株式会社中山事務所 |
波力発電装置
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating KCNQ4-related hearing loss
|
WO2023056399A1
(en)
|
2021-10-02 |
2023-04-06 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
WO2023064811A1
(en)
|
2021-10-12 |
2023-04-20 |
Aspa Therapeutics, Inc. |
Methods and compositions for treating leukodystrophies
|
US20230241118A1
(en)
|
2021-10-20 |
2023-08-03 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
CA3235632A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
US20230270818A1
(en)
|
2021-11-02 |
2023-08-31 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
WO2023114901A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
TW202337476A
(zh)
|
2022-01-17 |
2023-10-01 |
瑞士商迪納柯公司 |
用於與肌肉萎縮蛋白有關之心肌病之基因療法組合物及治療
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
TW202346599A
(zh)
|
2022-02-08 |
2023-12-01 |
美商航海家醫療公司 |
Aav衣殼變異體及其用途
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(zh)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
經修飾之肌肉特異性啟動子
|
WO2023178220A1
(en)
|
2022-03-16 |
2023-09-21 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230409A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|